The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis

BACKGROUND: Besifloxacin ophthalmic suspension 0.6 % (Besivance(®); Bausch & Lomb, Rochester, NY, USA) was approved by the FDA in 2009 for the treatment of bacterial conjunctivitis, with a recommended 7-day dosing regimen. OBJECTIVE: The objective of this study was to compare the safety of besif...

Descripción completa

Detalles Bibliográficos
Autores principales: Malhotra, Ranjan, Ackerman, Stacey, Gearinger, Lynne S., Morris, Timothy W., Allaire, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851703/
https://www.ncbi.nlm.nih.gov/pubmed/24142473
http://dx.doi.org/10.1007/s40268-013-0029-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851703/
https://www.ncbi.nlm.nih.gov/pubmed/24142473
http://dx.doi.org/10.1007/s40268-013-0029-1

Ejemplares similares